A Study of PER-001 in Participants With Diabetic Retinopathy

A Study of PER-001 in Participants With Diabetic Retinopathy

Brief Summary:
This is a Phase 2a, randomized, single-masked (participant), sham controlled clinical study.

Condition or disease

Diabetic Retinopathy
Drug: PER-001 Intravitreal Implant – Low Dose Drug: PER-001 Intravitreal Implant – High Dose Drug: PER-001 Intravitreal Implant – Sham
Phase 2

Detailed Description:
This clinical study is a randomized, single-masked (participant) study to further investigate the ocular and systemic safety and tolerability of the two dose levels of PER-001 Intravitreal Implants in participants with diabetic retinopathy. Participants who meet entry criteria will be randomized to receive either dose of PER-001 or sham control. A total of approximately 24 participants (12 in each Cohort, will be randomized).

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 25, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine